KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Total Liabilities (2016 - 2025)

West Pharmaceutical Services' Total Liabilities history spans 17 years, with the latest figure at $1.1 billion for Q3 2025.

  • For Q3 2025, Total Liabilities rose 14.23% year-over-year to $1.1 billion; the TTM value through Sep 2025 reached $1.1 billion, up 14.23%, while the annual FY2024 figure was $961.1 million, 1.33% up from the prior year.
  • Total Liabilities for Q3 2025 was $1.1 billion at West Pharmaceutical Services, up from $1.0 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.1 billion in Q3 2025 and bottomed at $846.0 million in Q3 2022.
  • The 5-year median for Total Liabilities is $935.1 million (2025), against an average of $939.5 million.
  • The largest annual shift saw Total Liabilities grew 20.42% in 2021 before it decreased 10.03% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $978.4 million in 2021, then dropped by 4.75% to $931.9 million in 2022, then grew by 1.78% to $948.5 million in 2023, then increased by 1.33% to $961.1 million in 2024, then grew by 9.7% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for WST's Total Liabilities are $1.1 billion (Q3 2025), $1.0 billion (Q2 2025), and $935.1 million (Q1 2025).